Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Lipopolysaccharide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    29 result(s) found for: Lipopolysaccharide. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2012-004622-14 Sponsor Protocol Number: LPS_concmed_controlled Start Date*: 2013-02-01
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Concentration/meditation as a novel means to limit inflammation: a randomized controlled pilot study
    Medical condition: Possibe future indications: inflammatory conditions in general, auto-immune diseases
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-002390-21 Sponsor Protocol Number: Oxygen_Inflammation Start Date*: 2013-09-03
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Effects of oxygen status on endotoxemia induced inflammation and Hypoxia Inducible Factor 1-a. A pilot proof of principle study.
    Medical condition: Possible future indications: inflammatory conditions in general, autoimmune diseases
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-005537-30 Sponsor Protocol Number: NL_ABR51923 Start Date*: 2015-06-09
    Sponsor Name:Radboud university medical center
    Full Title: Does ticagrelor modulate the inflammatory respons to human endotoxemia?
    Medical condition: We will study in male healthy volunteers whether ticagrelor modulates the inflammatory response to the administration of lipopolysaccharide (LPS) in humans in vivo.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002860-86 Sponsor Protocol Number: 2007/099 Start Date*: 2007-06-26
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: The adenosine receptor; a new pharmacological tool in the treatment of sepsis.
    Medical condition: Systemic inflammatory response
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-002706-36 Sponsor Protocol Number: VASOPRESSOR-LPS Start Date*: 2016-01-06
    Sponsor Name:Radboudumc
    Full Title: The effects of different vasopressors on the innate immune response during experimental human endotoxemia, a pilot proof-of-principle study
    Medical condition: Possible future indications: infectious diseases which require vasopressor therapy.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-005687-97 Sponsor Protocol Number: NoSIRS Start Date*: 2013-06-20
    Sponsor Name:Medtronic Inc.
    Full Title: Effects of Transvenous Vagus Nerve Stimulation on Immune Response: a pilot study
    Medical condition: Possible future indications: inflammatory conditions in general
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-004023-31 Sponsor Protocol Number: LPS-Fluenz Start Date*: 2016-01-06
    Sponsor Name:Radboudumc
    Full Title: The effects of endotoxin challenge on the immune response elicited by a subsequent challenge with Fluenz™ in healthy volunteers, a pilot study
    Medical condition: Inflammatory conditions in general and immunosuppressive conditions is particular
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003067-22 Sponsor Protocol Number: PRISTINE Start Date*: 2012-11-19
    Sponsor Name:LUMC
    Full Title: Pneumonia treated with rifampicine attenuates inflammation
    Medical condition: Community acquired pneumonia CURB-65 class >1
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004862 10010120 Community acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-002584-90 Sponsor Protocol Number: D1511C00002 Start Date*: 2005-08-22
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD8309 on Airway Inflammation as Assessed in Induced Spu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-004396-35 Sponsor Protocol Number: 06078SE-A Start Date*: 2006-10-25
    Sponsor Name:Belfast City Hospital Trust
    Full Title: Investigation of the anti-inflammatory effects of simvastatin in a model of acute lung injury after inhalation of lipopolysaccharide by healthy volunteers
    Medical condition: Acute lung injury (ALI)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-000441-58 Sponsor Protocol Number: 08005DM-A Start Date*: 2009-01-22
    Sponsor Name:Belfast City Hospital
    Full Title: Investigation of the protective effects of keratinocyte growth factor (KGF) in a human lipopolysaccharide induced model of acute lung injury
    Medical condition: Acute lung injury
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2007-004584-22 Sponsor Protocol Number: D0520C00003 Start Date*: 2007-11-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover Study in Healthy Volunteers to Investigate the Effect of Oral Dosing with AZD9668 on Airway Inflammation as Assessed in Induced Spu...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010952 COPD LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-003850-25 Sponsor Protocol Number: PXVX-VC-200-006 Start Date*: 2018-12-04
    Sponsor Name:PaxVax Inc
    Full Title: A Phase 4 Study to Assess the Safety and Immunogenicity of VAXCHORA (Cholera Vaccine, Live, Oral) in Children 2 to <18 Years of Age
    Medical condition: Prevention of cholera
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10047398 Vibrio cholerae gastroenteritis LLT
    20.0 100000004862 10008632 Cholera due to Vibrio cholerae LLT
    20.0 100000004862 10008634 Cholera, unspecified LLT
    20.1 100000004862 10008633 Cholera due to Vibrio cholerae el tor LLT
    20.1 100000004862 10045658 Unspecified cholera LLT
    20.0 100000004862 10047397 Vibrio cholera gastroenteritis LLT
    20.0 100000004848 10070172 Vibrio cholerae test positive LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2011-002222-46 Sponsor Protocol Number: 36688 Start Date*: 2013-09-04
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: In vivo effects of C1-esterase inhibitor on innate immune response during endotoxemia in human - VECTOR-II study A randomized controlled pilot study
    Medical condition: Inflammation, SIRS and endotoxemia
    Disease: Version SOC Term Classification Code Term Level
    15.1 10018065 - General disorders and administration site conditions 10061218 Inflammation PT
    15.1 10021881 - Infections and infestations 10060412 Septicaemia due to Escherichia coli (E. coli) LLT
    15.1 100000004848 10051553 Complement factor C1 LLT
    15.1 10021881 - Infections and infestations 10040047 Sepsis PT
    15.1 10018065 - General disorders and administration site conditions 10062357 SIRS LLT
    Population Age: Adults Gender: Male
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2020-006023-33 Sponsor Protocol Number: SIMFIB Start Date*: 2021-10-26
    Sponsor Name:Institut d’Investigacions Biomèdiques August Pi i Sunyer
    Full Title: Efficacy of simvastatin reducing liver fibrosis in patients with advanced fibrosis due to alcohol: a randomized, double-blind, placebo-controlled clinical trial.
    Medical condition: reduction of liver fibrosis in patients with advanced fibrosis due to alcohol
    Disease: Version SOC Term Classification Code Term Level
    20.1 10019805 - Hepatobiliary disorders 10001627 Alcoholic liver disease PT
    20.0 10019805 - Hepatobiliary disorders 10019668 Hepatic fibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-003325-22 Sponsor Protocol Number: 2022-15944 Start Date*: 2023-01-25
    Sponsor Name:RadboudUMC
    Full Title: The immunomodulatory effect of sugammadex after total hip replacement surgery under neuraxial anaesthesia: a pilot study
    Medical condition: Hip osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005611-16 Sponsor Protocol Number: 52003 Start Date*: 2015-03-16
    Sponsor Name:Academic Medical Center, University of Amsterdam
    Full Title: Effect of Intravenous Administration of C1-inhibitor on Inflammation and Coagulation after Bronchial Instillation of House Dust Mite Allergen and Lipopolysaccharide in Allergic Asthma Patients
    Medical condition: Mild asthmatics with house dust mite allergy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-020141-26 Sponsor Protocol Number: D3320C00001 Start Date*: 2010-08-30
    Sponsor Name:AstraZeneca AB
    Full Title: A Single-Centre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase IIa Study to Investigate the Effects of 100mg AZD2423 as an oral tablet in Subjects with Mild COPD Following Seg...
    Medical condition: Chronic Obstructive Pulmonary Disease (COPD)
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038738 - Respiratory, thoracic and mediastinal disorders 10010952 COPD LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-000228-20 Sponsor Protocol Number: 16012020001 Start Date*: 2020-08-28
    Sponsor Name:Medical University of Graz
    Full Title: Probiotic dietary Intervention in Polycystic Ovary Syndrome – A Randomized Controlled Trial
    Medical condition: Polycystic Ovary Syndrome (PCOS) is a hormonal and metabolic disorder affecting up to 20 percent of women worldwide, depending on diagnostic criteria. A very common definition of PCOS based on the ...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002451-19 Sponsor Protocol Number: 2022-15754 Start Date*: 2022-09-22
    Sponsor Name:Radboudumc
    Full Title: Deep versus moderate neuromuscular blockade during total HIP replacement surgery to improve POstoperative quality of recovery and immune function: a randomized controlled study
    Medical condition: Hip osteoarthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 02:41:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA